Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%. Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80 and first-quarter 2026 ...

Pricing challenges in Abbott’s nutrition business and lower than expected sales of continuous glucose monitors drove down the ...

Abbott missed Wall Street estimates for quarterly revenue on Thursday, hit by weakness in its diagnostic business which has been volatile due to sharp decline in COVID-19 testing demand and a freeze ...

Abbott Laboratories (NYSE:ABT) reported fourth-quarter earnings that met expectations but missed on revenue, sending shares down 4.8% as investors reacted to the shortfall and weaker-than-expected ...

The Texas power grid system, which failed during a previous winter storm, could be put to the test this weekend as the region faces subfreezing temperatures and dangerous wind chills.

Abbott Laboratories (ABT) stock falls as underperformance in the company's Nutrition segment leads it to record lower than expected Q4 sales. Read more here.

Abbott Laboratories (NYSE:ABT) shares fell about 4.8% after the company reported fourth-quarter results that met earnings ...

Jan 22 (Reuters) - Abbott forecast current-quarter profit below estimates after missing Wall Street expectations for ...

ADJUSTED EARNINGS: Stripping out certain one-time items, earnings are forecast to come in at $1.50 a share. That compares with adjusted earnings of $1.34 a share a year earlier. REVENUE: Quarterly ...

Abbott Laboratories (NYSE: ABT) doesn’t just pay dividends. It grows them. For 52 consecutive years. That’s Dividend King ...

The following segment was excerpted from the Alger Mid Cap Focus Fund Q4 2025 Commentary.Class A shares of the Alger Mid Cap ...